Ticker

Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report) and Atrinsic (NASDAQ: PTIX - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability. Insider and Institutional Ownership 88.1% of Vanda Pharmaceuticals

Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW YORK CITY, NY / ACCESS Newswire / March 17, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related neuropsychiatric disorders,…

Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class treatments for stress-related disorders, including treatment-resistant depression and anxiety,…

Atrinsic Inc. (NASDAQ: PTIX - Get Free Report)'s stock price was up 10.9% during trading on Tuesday. The company traded as high as $0.50 and last traded at $0.50. Approximately 2,974 shares traded hands during trading, a decline of 96% from the average daily volume of 77,387 shares. The stock had previously closed at $0.4507.

Atrinsic (NASDAQ: PTIX - Get Free Report) and Praxis Precision Medicines (NASDAQ: PRAX - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Analyst Ratings This is a summary of recent